Peter H. O'Donnell to Prostatic Neoplasms, Castration-Resistant
This is a "connection" page, showing publications Peter H. O'Donnell has written about Prostatic Neoplasms, Castration-Resistant.
Connection Strength
0.119
-
Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93.
Score: 0.119